Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- TDOC -24%, SGMO -22.7%, INOV -18.1%, BSQR -15.9%, TEGP -14.6%, BBRG -13.9%, FRSH -13.5%, QUIK -11%, GI-10.1%, (also files for $100 mln mixed securities shelf offering and 6,060,444 shares common stock offering by selling stockholders; announces recent FDA clearance and US launch of Lumos with Adaptive Matrix Imaging)
- NSYS -9.7%, UHAL -9.5%, IMGN -8.8%, AMRN -8.7%, AME -8.2%, HOS -7.9%, TRIP -7.2%, PMT -6.4%, FRGI -6.1%,CHK -5.3%, GPOR -5%, GOLD -4.9%, CF -4.8%, MET -4.5%, IRG -4.3%, VTAE -4.3%, ANDE -4.1%, LGCY -4%
- XOMA -3.9%, HIVE -3.8%, ALB -3.6%, ETP -3.6%, FOXA -3.5%, (also discloses that it eliminated the previously-announced suspension of voting rights of shares of Class B Common Stock held by stockholders who are not U.S. citizens ),ETE -3.4%, BDX -3.3%, CBPX -3.2%, (also expands share repurchase program to $100 mln from $50 mln), NOK -3.2%,LNC -3%, MED -2.9%, CTL -2.7%, ADRO -2.6%, TNK -2.4%, GERN -2.2%, G -2.1%, HSIC -2%
- PRU -1.9%, (also authorized a $500 mln increase to the existing share repurchase authorization for calendar year 2016),EVHC -1.9%, AGU -1.9%, TSO -1.9%, (also increases quarterly dividend), BLUE -1.8%, AWK -1.8%, NAVB -1.8%, DYN-1.7%, CXW -1.7%, LODE -1.7%
- PEGA -1.4%, SYNC -1.3%, CCOI -1.3%, HMHC -1.2%, SBH -1.2%, NLY -1.1%, CIM -1.1%, OAS -1.1%
Other news:
- MNTA -14.8% (discontinues further accrual of its Phase 2 trial evaluating necuparanib in combination with Abraxane and gemcitabine in patients with advanced metastatic pancreatic cancer)
- PQ -9.5% ( in 10-Q adds a potential bankruptcy filing to list of risk factors - Was not part of 10-Q filed in May)
- AMRN -7.5% (announces that the FDA agreed to an amendment of its special protocol assessment agreement for the REDUCE-IT cardiovascular outcomes study)
- ADAP -4.9% (received notice from the FDA that a partial clinical hold has been placed on its planned pivotal study of NY-ESO SPEAR T-cell therapy in myxoid round cell liposarcoma )
- RYAM -4.7% (announces public offering of 1,250,000 shares of the Company's Series A Mandatory Convertible Preferred Stock)
- CP -3.3% (Canadian Pacific confirms the commencement of a public offering of 9,840,890 of common shares by certain funds managed by Pershing Square; Canadian Pacific and Canadian Natl Rail (CNI) agree to settle lawsuit commenced by CNI in August 2015 against CP, certain of its employees and an officer, alleging misuse of confidential information, without any admission of liability on the part of CP)
- PCLN -0.6% (following TRIP earnings)
- EXPE -0.5% (following TRIP earnings)
Analyst comments:
- GRMN -1.6% ( downgraded to Underperform at BofA/Merrill)